The Therapy Hour
Tech, Health•

The Therapy Hour

Mar 17, 2026

The therapy room is quiet except for the soft clicking of a tablet, a steady, mechanical rhythm that fills the pauses between prompts as a technician kneels on the carpet across from a small boy and holds up a laminated card—a horse—waiting for the response that will register as progress.

The boy studies it, his eyes moving from the edges to the center as if the image might change if he looks long enough, and then he taps the card with his finger.

“Horse,” he says, the word landing clearly enough to be counted.

The technician smiles, taps the screen, and logs the answer, another data point secured inside a program designed to build something larger—language, routine, the fragile scaffolding of independence—while down the hallway his mother waits with a paper cup of coffee, watching the clock as the hour advances in quiet increments.

“How’d he do?” she asks when the door opens briefly, her voice low enough not to interrupt the session.

“Good,” the technician says, already half-turned back toward the room. “He’s getting it.”

The reassurance is real, but it exists alongside something else that does not appear in the exchange. The technician guiding the session earns less than twenty dollars for the hour, while that same hour can be billed to Medicaid for several hundred, and the difference between those two numbers is not incidental—it is the structure holding the room in place.

Autism therapy in the United States now runs on a simple unit that carries more weight than it first appears. When care is reimbursed by the hour, the hour becomes the product, and once that unit is fixed, the system begins organizing itself around producing, tracking, and expanding it.

Across the country, thousands of rooms like this one operate inside that logic, and over the past few years autism therapy has become one of the fastest-growing categories of spending within Medicaid, the joint federal–state program that insures more than ninety million Americans. What appears inside the room as incremental progress accumulates outside it as measurable cost.

In 2019, Medicaid spent about $660 million nationwide on autism therapy; by 2023, that figure had reached roughly $2.2 billion, transforming a once-specialized treatment field into a large and rapidly expanding industry.¹ The growth reflects something real, because diagnoses have increased steadily, with federal estimates placing roughly one in 31 American children somewhere on the spectrum, and families searching for help are not imagining the need.¹

Inside clinics, progress remains granular—a word spoken clearly, a task completed without prompting, a gesture repeated until it holds—while outside clinics the same hour converts directly into a claim, processed, reimbursed, and folded into a system that treats time as both care and commodity.

Medicaid pays providers through hourly reimbursement, and once a clinic is approved each hour delivered becomes billable, supported by a funding structure in which the federal government often covers about 70 percent of the cost.² That combination—hourly billing paired with a guaranteed payer—creates conditions where expansion follows a predictable path rather than a speculative one.

Markets do not need to be invented under those conditions. They emerge as clinics open in office parks and converted storefronts, as investors recognize the reliability of government-backed payment, and as hiring accelerates for technicians who deliver the sessions that generate the billable hours, even when those technicians remain near the bottom of the wage scale.

In Indiana, one company—Piece by Piece Autism Centers—illustrates how far that structure can extend once it begins scaling. Founded in 2019 by Meghann Mitchell, a former gymnastics coach who became a behavior analyst, the company followed a model that separates design from delivery: licensed analysts create treatment plans, while registered technicians conduct the sessions that fill the schedule.³

Those technicians typically earned under twenty dollars an hour, while the hours they produced were valued far higher within the reimbursement system, and the gap between labor cost and billable output widened as pricing moved.

When the company began, therapy was priced at about $200 per hour; by late 2023, the listed rate had climbed to roughly $1,600 per hour, with Medicaid reimbursing about 40 percent—around $640 for each hour delivered.⁴ Multiply that across dozens of patients and full weekly schedules, and the totals begin to accelerate in ways that are difficult to reconcile with the simplicity of the room where the work occurs.

In 2023, Indiana Medicaid paid the company $29 million to treat 84 children—about $340,000 per patient—and over five years total payments reached roughly $58 million.³⁵ Mitchell said the company complied with billing rules and passed multiple audits without findings of fraud, and when asked what justified the pricing increases she pointed not to a single cost driver but to decisions made alongside a business partner.⁴

The answer does not sit with the company alone, because the structure that allows it does not originate there.

Autism therapy operates in a part of healthcare that lacks a universal national standard for how many hours a child should receive, leaving treatment plans to be adjusted by clinicians over time, which helps families but removes a natural ceiling on expansion. National Medicaid data show an average of about fourteen hours of therapy per week per patient in 2023, yet many providers billed far more—thirty hours or more weekly for some children, effectively turning therapy into a full-time schedule.⁵

At that level, the system begins to tilt. Providers expand capacity, clinics multiply, and a growing workforce delivers the hours that sustain the model, while oversight moves more slowly, trailing the pace set by reimbursement.

Audits in states including Maine, Wisconsin, Indiana, and Colorado found documentation problems across every sample reviewed, including claims for therapy billed while children were resting or watching videos, a pattern that did not trigger widespread fraud findings but exposed how easily a system built on time can outpace the mechanisms designed to monitor it.²

By the time rules adjust, the structure is already embedded. Indiana eventually replaced its reimbursement formula with a flat rate of roughly $68 per hour, collapsing the previous pricing model almost overnight, and for clinics built on higher reimbursement the shift was not gradual but structural, forcing immediate adaptation.³

Back in the therapy room, the session continues as the technician presents another card and the boy hesitates, then answers, and the tablet records the result while the hour advances minute by minute, each entry marking both progress and completion.

His mother checks the clock again, then looks down at her coffee, which has gone cold without her noticing.

For the family, the hour carries weight that cannot be measured in billing codes. It is an investment in language, in independence, in the possibility that the boy will move through the world with fewer barriers than he would have without it, and that belief holds even when the system surrounding it operates on a different set of incentives.

“What if he needs more?” she asks when the session ends, her voice careful, as if the question itself might increase the answer.

“We can add hours,” the technician says, not hesitating this time.

The offer lands in two directions at once. It expands the child’s access to care, and it increases the volume of what the system recognizes as value, because each additional hour deepens both the intervention and the revenue attached to it.

The room remains what it was—quiet, controlled, built around repetition and small gains—but the structure surrounding it has already made a separate calculation, one that does not depend on any single child yet accumulates through all of them.

It teaches a child how to name the world.

And at the same time, without needing to declare it, it teaches the system how to turn that hour into something it can multiply.

Bibliography

1. The Wall Street Journal. “Autism Therapy Is Fastest-Growing Jackpot in Medicaid.” Investigation of Medicaid spending growth and autism diagnosis trends.

2. The Wall Street Journal. Reporting on Medicaid funding structure and multi-state audits of autism therapy billing.

3. The Wall Street Journal. Coverage of Piece by Piece Autism Centers and Indiana reimbursement changes.

4. The Wall Street Journal. Analysis of therapy pricing and reimbursement rules in Indiana Medicaid.

5. The Wall Street Journal. National Medicaid billing data examining therapy hours and provider concentration.

Continue →
The Moving Truck on Middle Street
Health, Regional•

The Moving Truck on Middle Street

Mar 14, 2026

Why thousands of American families lose the house long before they expect to.

The moving truck arrived on Middle Street in Portsmouth a little after nine on a cold February morning. On the kitchen table inside the house sat the bill that made it necessary: $42 an hour for a caregiver—more than $13,000 for this month alone.

The woman who had lived there since 1982 had hoped to stay in that house for the rest of her life. Her daughter had gone through the figures the night before and arrived at the same conclusion she had been approaching for months. Even working extra shifts at Elliot Hospital in Manchester, she couldn’t make it work.

By noon the house would be empty, and the proceeds from its sale would pay the first year of assisted-living care.¹

The moment felt sudden.

But the real decision had been made years earlier—back when the family still had options.

When the first falls began, they might have built a small accessory apartment behind the daughter’s house in Manchester. The place she shared with her kids was just big enough for them, but a modest ADU in the backyard could have kept her mother nearby while she continued working.

Or they might have sold the Portsmouth house earlier and moved into a smaller single-floor place they could share.

At the time, none of that seemed necessary. The house still felt safe. The mother insisted she was doing fine. And selling a home that had carried forty years of birthdays, winters, and illnesses felt premature.

So the costs rose gradually.

A few hours of help each day quietly became a full daily shift. In New Hampshire, those hours now cost $45 to $50 each, and caregivers are scarce enough that families often take whomever they can find. Before long the monthly bill climbs into five figures, and the decision that once felt emotional begins to look unavoidable.²

Many families assume Medicare will prevent exactly this situation.

It doesn’t.

Medicare pays for hospital care, doctor visits, and short rehabilitation stays after illness or surgery. What it does not cover is the daily labor of getting older—bathing, dressing, cooking, and helping someone move safely through a house. Those tasks fall under what the system calls custodial care and sit largely outside Medicare.³

The system surrounding aging in America was built to treat illness, not the long stretch of ordinary life that follows it.

Once families encounter that gap, the house becomes the financial reserve. Savings thin out first, retirement accounts follow, and eventually the only asset large enough to sustain ongoing care is the house itself.

The numbers escalate quickly. At $39 to $45 an hour, eight hours of daily help runs roughly $9,500 to $11,000 a month. When care stretches to twelve hours a day—as often happens after another fall or the early stages of dementia—the annual cost can climb past $200,000. Few middle-class families can carry that for long.⁴

Across the country, versions of this scene unfold every day: a kitchen table, a stack of bills, and the quiet realization that the house has become the last financial lever left.

The difficult truth is that the most workable solutions usually appear earlier, when the need still seems distant. A small apartment behind a daughter’s house. A move to a single-floor home closer to family. Selling sooner while the owner still has the strength to shape the next stage of life.

Once you begin noticing the pattern, it appears everywhere.

Families wait because the house feels permanent, yet aging quietly turns time into a financial force. Each year that passes narrows the range of choices.

In Quebec, the picture often looks different. Provincial programs and tax credits offset a large share of the cost of home-support services, and many towns quietly encourage housing arrangements that keep older residents close to family. A modest single-floor home in the Eastern Townships can keep someone independent for years longer than a large two-story New England house designed for a young family.⁵

Across much of the developed world, aging rarely begins with the question of whether to sell the house. In countries such as the Netherlands, Denmark, and Sweden, municipal home-care teams provide subsidized help with bathing, meals, and supervision as needs grow.⁶ Japan reached a similar place through a national long-term care insurance program created in 2000 that helps cover home aides and assisted living without forcing families to exhaust their savings first.⁷ In much of the world, the daily labor of aging sits inside the health-care system. In the United States, it still falls largely on families—and often on the house itself.

Across Maine, New Hampshire, and Vermont, the houses themselves add another complication. Bedrooms sit upstairs. Bathrooms are narrow. Icy driveways and long distances to grocery stores turn ordinary errands into risks.

None of those details matter when the owners are forty.

They matter a great deal at eighty.

The shift often begins with a fall or a hospital stay. Soon discharge planners start asking about supervision, and the house that once symbolized independence begins to look like a safety risk. Families begin touring assisted-living facilities.

Some are comfortable and well run, but places like that often cost thousands of dollars each week. Others are cheaper and feel less like homes than institutions.

So families hold on to the house as long as they can.

Roughly three-quarters of Americans say they want to age at home. Yet the system surrounding those homes was never designed for it. American medicine treats emergencies brilliantly—heart attacks, strokes, broken hips—but the long years afterward, when someone simply needs help every day, fall into a gray space between housing and health care.

That gap is where houses quietly disappear.

Back on Middle Street, the movers closed the truck doors while the daughter helped her mother into the car’s passenger seat. From the sidewalk the old Portsmouth house looked exactly as it always had—the same porch railing, the same narrow staircase inside that had carried forty years of footsteps.

Homes protect us for a long time.

Eventually the arithmetic changes. The house that once felt like security becomes the asset that keeps everything else afloat.

From the sidewalk, the place on Middle Street looked unchanged.

But what looked like one family leaving a street was really the surface ripple of decisions made far beyond it.

⸻

Bibliography

1. Genworth Financial. Cost of Care Survey 2024. National survey documenting assisted-living and in-home care costs across the United States.

2. PHI National. Direct Care Workforce Data Center. Analysis of wages and workforce shortages among home-care aides in the United States.

3. Kaiser Family Foundation. Medicare and Long-Term Care Coverage. Overview of Medicare’s limits regarding custodial and long-term care services.

4. AARP Public Policy Institute. Valuing the Invaluable: Long-Term Care Costs and Family Caregiving. Research on financial impacts of long-term care on American families.

5. Gouvernement du Québec. Programme de soutien à domicile. Provincial programs and tax credits supporting aging at home in Quebec.

6. Organisation for Economic Co-operation and Development (OECD). Health at a Glance: Long-Term Care Across OECD Countries. Comparative analysis of home-care and elder-care systems across Europe.

7. Campbell, John C., and Naoki Ikegami. The Art of Balance in Health Policy: Maintaining Japan’s Low-Cost, Egalitarian System. Cambridge University Press; analysis of Japan’s national long-term care insurance program and home-support model.

Continue →
Health, Economy•

Selling Leukemia at 9:14 p.m.

Feb 20, 2026

The Strange Economics of Drug Advertising in the Only Country That Does It This Way

At 9:14 p.m., my dog, Sofia, was asleep, the dishes were done, and the television was selling leukemia.

Not bluntly. Not with a price tag. A woman in a linen shirt stood in a field of high grass, smiling at a horizon we couldn’t see. A calm voice described a rare blood disorder most Americans will never develop. She once felt tired, the voice said. She once worried. Now she lifts her grandson and laughs.

Then the voice shifted registers.

“Serious infections… organ damage… possible fatal outcomes…”

The warnings came at auctioneer speed while the golden retriever bounded through sunlight. The price was never mentioned.

I reached for the remote and muted it. I watched the tiny white type crawl across the bottom of the screen and realized I had a question I’d never quite formed:

Why are we advertising half-million-dollar drugs to people who don’t have the disease?

Only two countries on Earth allow prescription drugs to be marketed directly to consumers on television the way Americans know them: the United States and New Zealand.¹ In most wealthy democracies, if a medication requires a physician’s gatekeeping, the persuasion ends at the clinic door.

We chose differently.

In 1997, the FDA clarified how drugmakers could meet broadcast disclosure requirements—allowing television ads that named a drug and its use so long as viewers were directed elsewhere for full risk information.² The piano music began. The lifestyle montages followed. “Ask your doctor” entered the language like a civic duty.

Since then, pharmaceutical advertising has become one of the most reliable funding streams for American television. A Government Accountability Office report found manufacturers spent nearly $18 billion on direct-to-consumer advertising between 2016 and 2018—about $6 billion a year—with spending concentrated on a relatively small number of brand-name drugs.³

The country that pays the most for medicine is also the country most aggressively sold medicine.

That is not coincidence. It is architecture.

The phrase “ask your doctor” is not just polite branding. It is a behavioral lever. In a landmark study, standardized patients—actors trained to present scripted symptoms—visited real physicians. When those patients requested a specific antidepressant by name, prescribing rates rose significantly, even in clinically ambiguous scenarios.⁴ The request shifted the dynamic. Diagnosis became negotiation.

Advertising does not need to persuade millions. It needs to locate enough.

This is why the rare-disease campaigns are the most revealing. A biologic priced at $150,000 a year does not require ten million customers. It requires a few thousand insured ones. Capture 3,000 patients and you have $450 million in annual revenue. Manufacturing cost is often a fraction of that. Pricing reflects exclusivity, leverage, and what the system will bear.

It also reflects something more subtle: attention.

Many of the most powerful campaigns do not name a drug at all.

In 2016, viewers of General Hospital watched a beloved character receive a diagnosis of polycythemia vera—a rare blood cancer. The storyline was part of a disease-awareness partnership backed by Incyte, whose drug portfolio aligned with the condition’s molecular pathway.⁵ Oncologists publicly objected that a soap opera had become a clinical funnel.⁶

No brand name flashed across the screen. No price was mentioned.

But awareness spread.

During the Rio Olympics, Mylan ran heavy “unbranded” allergy awareness advertising at the height of the EpiPen pricing controversy.⁷ The campaign urged vigilance about severe allergic reactions. It did not need to say “EpiPen.” The rescue category was already clear.

More recently, Bristol Myers Squibb launched “Could It Be HCM?”—an unbranded awareness campaign fronted by NBA player Jared Butler, urging viewers to consider hypertrophic cardiomyopathy.⁸ Alexion produced film-style awareness projects around generalized myasthenia gravis, a rare autoimmune neuromuscular disease treated with high-cost biologics in its portfolio.⁹

These campaigns do not shout. They suggest. They invite. They lower the threshold at which normal human variance feels diagnostic.

Mass advertising for rare diseases is not about the masses. It is about finding the few.

Regulators have begun to respond.

In September 2025, the FDA announced a sweeping enforcement push, issuing roughly 100 cease-and-desist notices and thousands of warning letters related to misleading direct-to-consumer drug promotion.¹⁰ The action followed a White House memorandum directing health officials to ensure ads present true “fair balance” between benefits and risks.¹¹

For context: in 2023, the agency issued a single warning letter related to promotional violations. In 2024, none.¹²

When the cop stops writing tickets, the billboards multiply.

The new enforcement wave targeted high-visibility placements. Hims & Hers drew scrutiny over a Super Bowl advertisement promoting compounded weight-loss drugs without adequate risk disclosure.¹³ Eli Lilly and Novo Nordisk received warnings related to promotional communications judged to minimize or omit serious side effects.¹⁴ These were not obscure cable spots. They were mainstream cultural events.

Regulators are not banning ads. They are trying to close gaps that allow benefit-forward narratives to float above proportional risk context.

Yet the deeper question remains unresolved.

If the defense of high American drug prices is that we subsidize global innovation, why does that innovation require mass persuasion?

Part of the answer lies on the other end of the spectrum—the miracles.

In 2019, researchers published in the New England Journal of Medicine the case of a child with Batten disease who received a customized antisense therapy—milasen—designed specifically for her genetic mutation.¹⁵ It was a triumph of precision medicine. It was also a glimpse of a future where treatments are engineered for individuals.

Boston Children’s Hospital has described the research costs for such individualized programs as averaging roughly $1.6 million per case—astonishingly low by pharmaceutical standards, yet still reliant on extraordinary coordination and philanthropic support.¹⁶

The contrast is jarring.

On one side: bespoke cures built in months for a single child.

On the other: primetime commercials for six-figure therapies aimed at viewers who may not know they’re candidates.

Both exist in the same system.

And that system prices not at cost, but at leverage.

Insurance insulates patients from immediate sticker shock. Premiums absorb the difference. The signal becomes simple:

Why not ask?

The danger is not that Americans are uniquely fragile. It is that we have built an economy in which attention functions as a clinical input.

When enough viewers reinterpret fatigue, stiffness, distraction, or sadness through the lens of possibility, clinics feel the pressure. Some of those conversations save lives. Some accelerate overdiagnosis. Many are simply expensive.

Back in the living room, the news resumed. Sofia shifted and sighed.

I unmuted the television and listened to the next commercial break arrive. Another soft-lit couple. Another calm recital of catastrophic risks delivered over birdsong.

I wondered how many viewers would walk into appointments this week carrying a brand name they did not know last month. I wondered how many families with truly rare conditions were still fighting prior authorization while the awareness machine hummed.

We have built a healthcare system where miracles are real—and marketing is louder.

If we want the miracles to feel normal instead of luxurious, the solution is not silence. It is redesign.

Approve platforms once, not from scratch each time.

Pool risk so no insurer has an incentive to stall a cure.

Separate clinical education from revenue-dependent advertising.

Fund innovation transparently, and negotiate prices honestly.

Until then, the commercial break will continue doing clinical work.

And Sofia will keep sleeping through it.

⸻

Bibliography

1. Ventola, C. Lee. “Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic?” Pharmacy and Therapeutics 36, no. 10 (2011): 669–684. Describes the United States and New Zealand as the only countries permitting full direct-to-consumer prescription drug advertising.

2. U.S. Food and Drug Administration. “Consumer-Directed Broadcast Advertisements; Draft Guidance.” Federal Register, August 12, 1997. Formalized how manufacturers could satisfy broadcast disclosure requirements for DTC television ads.

3. U.S. Government Accountability Office. Prescription Drugs: Medicare Spending on Drugs with Direct-to-Consumer Advertising. GAO-21-380, June 2021. Quantifies DTC advertising expenditures and concentration among brand-name drugs.

4. Kravitz, Richard L., et al. “Influence of Patients’ Requests for Direct-to-Consumer Advertised Antidepressants.” Journal of the American Medical Association 293, no. 16 (2005): 1995–2002. Randomized trial showing that patient requests significantly increase prescribing rates.

5. Molteni, Megan. “The Tricky Ethics of Big Pharma’s Soft Sell on Soap Operas.” Wired, May 2017. Reports on the General Hospital polycythemia vera storyline backed by Incyte.

6. Garde, Damian. “Drama and Diagnosis: Soap Opera Cancer Plotline Puts Incyte in Hot Seat.” FiercePharma, 2016. Describes oncologist criticism of the PV storyline as a marketing mechanism.

7. Robbins, Rebecca. “EpiPen’s Olympic Advertising Blitz.” STAT, August 2016. Details Mylan’s unbranded allergy awareness campaign during Olympic broadcasts.

8. DeAngelis, Christina. “Utah Jazz Rookie Opens Up About Heart Diagnosis in BMS Awareness Campaign.” FiercePharma, 2022. Covers Bristol Myers Squibb’s “Could It Be HCM?” unbranded awareness effort.

9. DeAngelis, Christina. “AZ’s Alexion Spotlights gMG in Awareness-Raising Film.” FiercePharma, 2023. Discusses Alexion’s documentary-style campaign around generalized myasthenia gravis.

10. U.S. Food and Drug Administration. “FDA Launches Crackdown on Deceptive Drug Advertising.” Press release, September 2025. Announces issuance of approximately 100 cease-and-desist notices and thousands of warning letters.

11. The White House. “Memorandum for the Secretary of Health and Human Services and the Commissioner of Food and Drugs.” September 2025. Directs federal agencies to ensure truthful and balanced DTC drug advertising.

12. Gardner Law Firm. “FDA Sends 100+ Cease-and-Desist Letters: A Warning to Industry on DTC Pharmaceutical Advertising.” 2025. Notes the sharp increase in enforcement compared to prior years.

13. Reuters. “U.S. FDA Chief Says Hims & Hers Super Bowl Ad Violated Drug Promotion Rules.” September 12, 2025. Reports regulatory concerns over Super Bowl weight-loss drug advertising.

14. Pharmaceutical Technology. “Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications.” 2025. Details warning letters related to promotional communications.

15. Kim, Jong-Hee, et al. “Patient-Customized Oligonucleotide Therapy for a Rare Genetic Disease.” New England Journal of Medicine 381 (2019): 1644–1652. Describes the development and administration of milasen for Batten disease.

16. Boston Children’s Hospital. “Custom Genetic Treatments and the Future of N-of-1 Medicine.” 2022. Discusses development costs and logistical challenges for individualized antisense therapies.

Continue →
Economy, Health•

Who Keeps the Lights On?

Feb 14, 2026

The labor we argue about is the labor that keeps us alive.

The code blue alarm goes off at 3:17 a.m.

Room 412. Male. Sixty-eight. Sudden neurological collapse.

The night nurse is already moving. The respiratory therapist swings the ventilator into position. A resident sprints down the hallway pulling on gloves. They work the protocol fast — oxygen, compressions, meds. The attending neurologist should be here in under five minutes.

Except tonight there isn’t one.

Two neurologists left last year. One retired. One moved to Toronto after his visa renewal stalled. The third — foreign-born, trained in the United States, board-certified — is waiting on paperwork tied up in a policy fight no one in this hallway voted on.

The patient dies at 3:42.

About 27% of physicians practicing in the United States were born outside the country.¹ Immigrants make up roughly 40% of home health aides.² More than half of farm laborers — about 54% — are immigrants.³

Those numbers are not symbolic. They are load-bearing.

By sunrise the hospital parking lot is full again. Coffee cups. Scrubs. Fluorescent lights humming. The building exhales and inhales, like it always does. And a significant share of the people who make that breathing possible were not born here.

We have built an economy that depends — quietly, structurally — on immigrant labor. Not in theory. In payroll spreadsheets. In staffing charts. In night shifts no one tweets about.

Shift scenes.

Dawn in California’s Central Valley. A lettuce field that should be humming with workers is thin. The grower couldn’t fill the crew. By noon the sun will start to scorch the outer leaves. By tomorrow the crop will be compromised. By next week grocery prices will tick upward by pennies that accumulate into headlines about “inflation.”

Food does not pick itself.

Or go to a small town in Ohio. An 82-year-old widower needs help standing, bathing, managing medications. His daughter works two jobs. The home health aide who has kept him stable for two years — Filipino, meticulous, gentle — just left after her status grew uncertain. The agency hasn’t replaced her. There aren’t enough applicants.

Private home care now runs close to $10,000 a month in many markets. Families who can’t pay cash sign agreements that effectively place a lien against the house. When he dies, the home goes to the agency, not to his grandchildren.

Care does not provide itself. And it is not cheap.

While politicians argue about “shutdowns,” the workforce holding up the country is the one being framed as the threat.

You can debate enforcement mechanisms. You can debate asylum law. You can debate border management.

You cannot deport arithmetic.

The United States is aging. Birth rates are below replacement. In sector after sector, employers cannot fill roles that are physically demanding, emotionally exhausting, or highly specialized. Rural hospitals recruit internationally because they have no choice. Farmers advertise locally and come up short. Construction firms delay projects for lack of crews.

Remove immigrant labor from agriculture tomorrow and crops rot. Remove foreign-born doctors from certain regions and wait times spike or entire specialties disappear. Pull immigrant construction crews off job sites and housing shortages intensify. Eliminate immigrant home health aides and families collapse under the weight of unpaid caregiving.

This isn’t a theory. It’s the staffing chart.

The same counties most animated about deportation often depend most heavily on immigrant nurses, technicians, and farmworkers. That dependency isn’t ideological. It’s functional. It shows up in harvest schedules and ER wait times, not campaign ads.

And here’s the quiet part no one likes to say out loud: immigrants do not just fill jobs Americans “won’t do.” They fill jobs America cannot currently staff at scale.

The ICU does not care about rhetoric. The crop does not care about slogans. The 82-year-old man does not care about cable news.

He cares whether someone shows up at 7:00 a.m. to help him stand.

The country runs on arguments. It also runs on labor.

Only one of those keeps the lights on.

⸻

Bibliography

1. Kaiser Family Foundation, “What Role Do Immigrants Play in the Hospital Workforce?” June 17, 2025. Reporting that approximately 27% of U.S. physicians are foreign-born.

2. Migration Policy Institute, “Immigrant Health-Care Workers in the United States,” April 7, 2023. Analysis showing immigrants comprise roughly 40% of home health aides.

3. U.S. Department of Agriculture Economic Research Service, “Farm Labor,” latest data tables. Reporting that approximately 54% of U.S. crop farmworkers are immigrants.

Continue →
The Waiting Room
Health, Tech•

The Waiting Room

Feb 13, 2026

The Emergency That Learned to Stay

The exam room smells like hand sanitizer and powdered gloves — that sharp, clean scent that promises order. It’s the smell of systems that are supposed to work.

Dr. Dolly Lucio Sevier smells it every day.

This morning she’s trying to calm a five-year-old boy who can’t explain why he keeps coughing. His mother hands her a plastic envelope stuffed with discharge papers from three different detention facilities. The medication lists don’t match. The dates don’t line up.

The system has already processed the child.

What it has not done is keep him medically intact.

That is the mechanism.

Emergency immigration authority is built to move people quickly across facilities and jurisdictions. Pediatric care is built to follow a patient over time. When those two systems intersect, speed breaks continuity, and continuity is what keeps children stable.

The boy laughs anyway, pressing a toy truck into the paper lining of the exam table, drawing roads that connect nothing. His breathing rattles when he does.

Sevier flips through the paperwork slowly. Not because she needs time to read it, but because parents watch doctors carefully in moments like this. They are looking for signs that everything makes sense.

The forms do not make sense.

She asks where the boy received his last treatment. The mother traces her finger along a facility name printed in faint ink and shrugs. She lost track after the second transfer.

The symptoms are manageable.

The medical history is not.

Over the past several years, Sevier has testified before Congress about cases like this. Immigration enforcement rarely arrives in pediatric medicine as policy. It arrives as missing prescriptions, interrupted vaccination schedules, and custody records that travel more reliably than treatment records.

“When children are moved repeatedly through facilities, their medical care often becomes fragmented, incomplete, or lost entirely,” she told lawmakers.¹

That fragmentation is not an accident. It is a consequence of how the system is designed to operate under emergency authority—fast, flexible, and indifferent to continuity.

In pediatric medicine, continuity is the treatment.

Asthma worsens when inhalers don’t follow the child. Respiratory infections escalate when monitoring stops between transfers. Chronic conditions that require stability encounter a system that resets the clock every time a child moves.

The emergency begins somewhere else.

It lands here.

Yazmin Juárez experienced that speed directly. She crossed the border seeking asylum with her nineteen-month-old daughter, Mariee. During detention, the toddler developed a fever and persistent cough. Juárez later testified that she repeatedly asked staff for medical care.

“My baby was coughing and had a fever. I told them she was sick, and they told me she was fine,” she said under oath.²

Mariee died soon after release.

A federal investigation later concluded that medical failures during detention contributed to her death.² The system had processed her case. It had not sustained her care.

The same pattern appeared in the death of seven-year-old Jakelin Caal Maquin. She developed dehydration and shock while in Border Patrol custody. Her father described the final hours without interpretation.

“She had a fever, and she started vomiting. They took her to the hospital, but it was too late.”³

After these deaths, screening protocols were revised.

But screening is intake.

Continuity is survival.

Dr. Colleen Kraft of the American Academy of Pediatrics saw the downstream effects during facility visits.

“When you take children away from their parents and place them in these detention settings, the damage can be profound and long lasting,” she said.⁴

The damage does not remain inside detention.

It follows.

In Nashville, school social worker Ana López watched a third-grade student disappear mid-semester after a workplace raid detained the child’s mother. Teachers prepared report cards with nowhere to send them. Medical files and counseling notes sat in the office, disconnected from the child they belonged to.

“We weren’t just missing a student,” López said later. “We were missing everything that kept her stable.”⁵

The system had moved faster than the institutions around it.

That mismatch does not resolve itself.

In Los Angeles County, public-health officials observed declines in vaccination participation following enforcement surges. Outreach workers reported parents delaying clinic visits out of fear that records might expose family members.

“Fear of enforcement has reduced participation in preventive care and vaccination programs,” the department concluded.⁶

Fear does not appear in enforcement data.

It appears later, in missed appointments and untreated illness.

Back in the exam room, Sevier notices another pattern. Families hesitate before answering questions. They ask whether medical records are private. They want to know who can see what.

Trust becomes a clinical variable.

And trust, once broken, behaves like a missing medication—it changes outcomes long after the initial event.

Emergency authority is designed to move quickly. Hospitals, schools, and public-health systems are designed to move slowly. When those speeds collide, the slower systems don’t accelerate.

They absorb the damage.

Over time, emergency enforcement stops feeling temporary. It becomes embedded in how institutions operate. Clinics adapt intake procedures. Schools track absences differently. Public-health departments adjust outreach strategies around fear rather than access.

What began as a surge becomes structure.

The most visible numbers appear in press releases—detentions, transfers, encounters. The less visible consequences accumulate in exam rooms, attendance records, and vaccination gaps.

Sevier sees those consequences in fragments.

Another child arrives with uncontrolled asthma after multiple transfers. The symptoms stabilize once medication resumes. The harder task is reconstructing care across incompatible records, gaps in treatment, and missing information.

The plastic envelope rustles as she opens it again. Dry. Creased. Traveled.

Emergency authority changes policy quickly.

It changes systems slowly.

By the time those changes are visible, they no longer resemble emergency. They resemble normal operations, with the same disruptions repeating under different names.

The sanitizer still smells clean.

The paperwork still smells like paper.

The waiting room still fills.

And children continue arriving with envelopes that document where they have been while revealing almost nothing about the care that followed them there, moving through a system that processes them efficiently while quietly losing track of what keeps them well.

⸻

Bibliography

1. U.S. House Committee on Oversight and Reform. Testimony of Dr. Dolly Lucio Sevier. Congressional record on pediatric care disruptions in immigration detention.

2. U.S. House Committee on Oversight and Reform. Testimony of Yazmin Juárez. Documentation of medical care failures leading to death of Mariee Juárez.

3. Associated Press; Washington Post. Coverage of the death of Jakelin Caal Maquin (2018). Reporting on medical events in Border Patrol custody.

4. American Academy of Pediatrics. Statements by Dr. Colleen Kraft following detention facility visits. Pediatric assessment of psychological and medical harm.

5. ACLU; education advocacy reporting on student displacement. Documentation of school and medical record disruption following enforcement actions.

6. Los Angeles County Department of Public Health. Vaccination participation analysis following enforcement activity. Evidence of reduced preventive care utilization.

Continue →
Economy, Health•

Best-in-World, On Purpose

Jan 2, 2026

A Blueprint for Replacing America’s Health Care System With One That Works

It starts the way so many American health care stories start now: with a calendar.¹

Not a diagnosis. Not a lab result. A date circled in red, six months out, when the insurance plan renews and the math might finally stop working. Until then, you ration refills, postpone scans, and make a quiet inventory of what you can afford to ignore. People don’t talk about this part much—the way time itself becomes a cost center—but it’s everywhere if you listen closely enough.²

By 2028, the United States will face a choice it has postponed for half a century. We can keep pretending our system is merely inefficient, or we can admit what it actually is: a structurally inverted machine that maximizes extraction at the expense of care. Fixing it won’t require a miracle. It will require discipline, sequencing, and a willingness to stop subsidizing failure.³

The good news—rare in this domain—is that we already know how to build best-in-world health care. The evidence is sitting in plain sight, across borders and within our own system. The problem has never been design. It’s been power.⁴

The first rule of repair is to stop confusing health care with insurance.

America does not have a health care system so much as a payment labyrinth that happens to include hospitals. We spend nearly twice as much per capita as other wealthy nations and get less life expectancy, worse chronic disease control, and higher maternal mortality in return.⁵ That gap is not clinical. It is administrative and political.⁶

A serious post-2028 plan starts by collapsing the number of payers—not to one overnight, but to a disciplined, standardized core. The fastest path is not a sudden leap to single payer, which would trigger institutional panic and endless litigation. It is a public option that is boring, universal, and impossible to opt out of over time.⁷

Medicare already exists. It works. It is popular. The trick is to expand it downward and outward—first to everyone over 55, then to children, then to anyone who wants in—while simultaneously standardizing reimbursement rules across private plans. The goal is not to outlaw private insurance. It is to make it redundant.⁸

This matters because cost control does not come from price caps alone. It comes from simplicity. Every hospital administrator in America can tell you how many staff hours are burned reconciling billing codes across dozens of insurers. Eliminate that friction, and you free billions before touching a scalpel.⁹

But coverage is only the chassis. The engine is primary care—and this is where the American system quietly collapses.

We have built a country where it is easier to see a specialist than a generalist, easier to get a procedure than a conversation. That is not an accident. It is a reimbursement choice.¹⁰ If you want best-in-world outcomes, you pay for continuity, not heroics.¹¹

The post-2028 plan must do something radical by American standards and utterly mundane elsewhere: guarantee every person a primary care clinician with a capped panel size and a salaried model. No fee-for-service hamster wheel. No incentive to rush. Just time, accountability, and prevention.¹²

Countries that do this—quietly, relentlessly—catch disease earlier, spend less on catastrophic interventions, and trust their systems more. We know this because we can measure it.¹³ The resistance is not empirical. It is cultural and financial.

Which brings us to drugs—the most visible, obscene failure in the American model.

The United States subsidizes global pharmaceutical innovation and then pretends this is an act of generosity rather than leverage. We pay the highest prices in the world for medications whose research we often helped fund, then forbid our own government from negotiating aggressively on our behalf.¹⁴ This is not market capitalism. It is self-imposed extortion.¹⁵

A best-in-world system after 2028 would do three things simultaneously. It would expand federal price negotiation to all high-volume drugs. It would enforce international reference pricing. And it would break the patent abuse pipeline that allows minor reformulations to reset monopolies indefinitely.¹⁶

None of this requires new science. It requires spine.

The same applies to hospitals.

The quiet secret of American health care costs is that they are driven less by wages or technology than by consolidation. Over the past two decades, hospital systems have swallowed competitors, negotiated higher prices, and justified it all in the language of “efficiency.” The result has been fewer choices, higher bills, and no measurable improvement in outcomes.¹⁷

A serious reform agenda uses antitrust law as health policy. It blocks further consolidation. It forces price transparency that actually means something. And it ties nonprofit hospital status to measurable community benefit, not branding exercises.¹⁸

If a hospital receives tax exemptions, it should prove—annually—that it is reducing uncompensated care, expanding access, and improving outcomes in its service area. Otherwise, it pays taxes like everyone else.¹⁹

Then there is the workforce.

America does not have a doctor shortage so much as a maldistribution crisis wrapped in educational debt.²⁰ We train clinicians at enormous cost, then funnel them into subspecialties and urban centers because that is where survival is financially possible.²¹

Fixing this is not complicated. It requires tuition-free medical and nursing education tied to service commitments, expanded scope-of-practice for non-physician clinicians, and immigration policies that welcome trained health workers rather than wasting their skills.²²

Other countries treat health workforce planning as infrastructure. We treat it as an accident. That alone explains much of the gap.²³

Technology, meanwhile, needs to be demoted from savior to tool.

Electronic records should talk to each other. Data should follow patients. AI should reduce clerical burden, not generate new billing games. The measure of success is not innovation theater but minutes returned to care.²⁴

And yes, this all costs money—just less than what we already spend badly.²⁵

The political mistake reformers make is arguing that better health care requires higher spending. The truth is harsher and more persuasive: we are already paying for a Rolls-Royce system and driving it into a ditch.²⁶ The task is to reallocate, not explode the budget.

The sequencing matters. Coverage expansion first. Cost controls embedded early. Workforce reform alongside reimbursement change. Drug pricing in parallel. Antitrust throughout.²⁷ Do this in pieces, transparently, with pilots and metrics, and the panic subsides.

What cannot happen—what has failed every time—is half-reform. Tweaks that preserve the extraction model while promising relief later.²⁸ That path leads exactly where we are now.

The moral argument, finally, is not abstract.

A system that ties survival to employment, geography, and luck is not merely inefficient. It is corrosive. It teaches people to delay care, to hide illness, to fear time. It turns health into a private gamble and then acts surprised when the house wins.²⁹

Best-in-world health care after 2028 is not a fantasy. It is a decision. Other countries made it decades ago. We have simply been negotiating with the wrong stakeholders.³⁰

If the next administration wants a legacy that actually lasts, it will stop asking whether America can afford universal, affordable care—and start asking why we tolerate anything less.³¹

⸻

Biibliography

1. Institute of Medicine. Hidden Costs, Value Lost: Uninsurance in America. National Academies Press, 2003. Foundational analysis of how delayed care and insurance gaps create cascading health and financial harm.

2. Kaiser Family Foundation. “Americans’ Challenges with Health Care Costs.” KFF, 2023. Survey data documenting widespread care deferral due to cost and insurance instability.

3. Woolhandler, Steffie, and David U. Himmelstein. “Administrative Waste in the U.S. Health Care System.” Annals of Internal Medicine 172, no. 2 (2020). Estimates the scale and structure of nonclinical waste.

4. Commonwealth Fund. Mirror, Mirror 2021. Comparative performance analysis of health systems across high-income countries.

5. OECD. Health at a Glance 2023. International comparisons of health spending, outcomes, and access.

6. Berwick, Donald M., Thomas W. Nolan, and John Whittington. “The Triple Aim.” Health Affairs 27, no. 3 (2008). Framework linking system design to outcomes and cost.

7. Oberlander, Jonathan. The Political Life of Medicare. University of Chicago Press, 2003. History of Medicare’s expansion and political durability.

8. Blahous, Charles. Medicare for All: Issues and Challenges. Mercatus Center, 2018. Analysis of expansion pathways and fiscal mechanics.

9. Tseng, Phillip et al. “Administrative Costs in U.S. Health Care.” Health Affairs 37, no. 11 (2018). Detailed breakdown of billing and insurance overhead.

10. Bodenheimer, Thomas, and Christine Sinsky. “From Triple Aim to Quadruple Aim.” Annals of Family Medicine 12, no. 6 (2014). Demonstrates how primary care structure affects outcomes and clinician burnout.

11. Starfield, Barbara. “Primary Care and Health.” Milbank Quarterly 83, no. 3 (2005). Landmark evidence linking primary care to population health.

12. OECD. Strengthening Primary Care Systems. OECD Publishing, 2020. Comparative policy analysis of salaried and panel-based care models.

13. Commonwealth Fund. “Primary Care Spending and Outcomes.” 2019. Empirical links between investment in primary care and system performance.

14. U.S. Government Accountability Office. Drug Pricing: Federal Investment in Drug Development. GAO-21-282, 2021. Documents public funding role in pharmaceutical R&D.

15. Kesselheim, Aaron S., et al. “The High Cost of Prescription Drugs in the United States.” JAMA 316, no. 8 (2016). Analysis of pricing mechanisms and patent abuse.

16. Congressional Budget Office. Options for Reducing the Deficit: Drug Pricing. 2022. Policy levers for negotiation and reference pricing.

17. Gaynor, Martin, Kate Ho, and Robert J. Town. “The Industrial Organization of Health Care Markets.” Journal of Economic Literature 53, no. 2 (2015). Evidence on consolidation and pricing power.

18. Federal Trade Commission. Policy Perspectives on Competition and Health Care. 2020. Antitrust frameworks applied to health systems.

19. Internal Revenue Service. Community Benefit Standard for Hospitals. IRS guidance and enforcement history.

20. Association of American Medical Colleges. The Complexities of Physician Supply and Demand. 2023. Workforce distribution analysis.

21. Salsberg, Edward, et al. “U.S. Physician Workforce.” Health Affairs 40, no. 2 (2021). Examines debt, specialty choice, and geographic imbalance.

22. National Academies of Sciences. The Future of Nursing 2020–2030. NASEM, 2021. Scope-of-practice and workforce reform recommendations.

23. OECD. Health Workforce Policies in OECD Countries. 2016. Comparative planning strategies.

24. Office of the National Coordinator for Health IT. Reducing Clinician Burden. HHS, 2020. Documentation of EHR-related inefficiencies.

25. Centers for Medicare & Medicaid Services. National Health Expenditure Accounts. CMS, 2023. Spending trends and allocation data.

26. Emanuel, Ezekiel J. Which Country Has the World’s Best Health Care? PublicAffairs, 2020. Comparative cost-performance critique.

27. Brookings Institution. Sequencing Health Reform. 2019. Analysis of phased reform strategies.

28. Hacker, Jacob S. The Divided Welfare State. Cambridge University Press, 2002. Explains partial reform failure dynamics.

29. Case, Anne, and Angus Deaton. Deaths of Despair. Princeton University Press, 2020. Links systemic stressors to mortality.

30. World Health Organization. Health Systems Governance. WHO, 2014. Institutional design principles for resilient systems.

31. Blendon, Robert J., et al. “Public Opinion and Health Reform.” New England Journal of Medicine 367 (2012). Evidence that durable reform aligns with public trust.

Continue →

Find articles